Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Emyria.
RELATED STOCKHEAD STORIES
Health & Biotech
Biocurious: From drug prices to efficiency drives, ASX biotechs await the ‘Trumpcare’ health fallout
Health & Biotech
Health Check: Actinogen powers ahead with key Alzheimer’s disease trial
Health & Biotech
Health Check: Could the White House be about to welcome LSD and magic mushrooms into the Oval Office?
Health & Biotech
Alive and Kicking: Lumos Diagnostics attracts ‘Twiggy’ Forrest as cornerstone holder in $10m raise
Health & Biotech
ASX Health Stocks: Imugene reveals promise in lymphoma trial, stock soars 27pc
Investor Guides
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
News
Market Highlights: ECB cuts rates, blow to psychedelics, and 5 ASX small caps to watch today
News
Rise and Shine: Everything you need to know before the ASX opens
ASX Small Caps and IPO Weekly Wrap: Everything sank except gold. What a mess.
News
Market Highlights: Fed comments trigger Wall Street selloff; and where is gold headed from here?
Health & Biotech
Weed Week: Medicinal cannabis will be here no matter what; and recent ASX pot winners
Health & Biotech
Weed Week: Blow to cannabis as Thailand backpedals on weed law; and recent ASX pot stock winners
News
In Case You Missed It: Spodumene finds and Google Cloud Partner designation
Health & Biotech
ASX Health Stocks: Emyria surges 19pc after granting of ‘Authorised Prescriber’ status by TGA
Health & Biotech
Weed Week: Massive study links cannabis to genetics and schizophrenia, and the best ASX weed stocks right now
Health & Biotech
Weed Week: Jamaican nettletree could be a new, cheaper option to source CBD, says scientists
Health & Biotech
